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The highly efficacious live-attenuated 17D yellow fever (YF) vaccine is occasionally 
associated with rare life-threatening adverse events. Modified vaccinia virus Ankara 
(MVA), a non-replicating poxvirus, has been used as a vaccine platform to safely deliver 
various antigens. A MVA-based YF vaccine (MVA-BN-YF) was tested with and without a 
non-mineral oil adjuvant in a hamster model of lethal YF disease and protective efficacy 
of this vaccine was compared with the 17D vaccine. The vaccine candidate MVA-BN-YF 
generated a protective response in hamsters infected with YFV that was comparable to 
protection by the live 17D vaccine. Similar levels of neutralizing antibody were observed 
in animals vaccinated with either vaccine alone or vaccine with adjuvant. Significant 
improvement in survival, weight change, and serum alanine aminotransferase levels were 
observed in vaccinated hamsters when administered 42 and 14 days prior to challenge 
with Jimenez YF virus (YFV). Neutralizing antibodies induced by MVA-BN-YF were trans-
ferred to naïve hamsters prior to virus challenge. Passive administration of neutralizing 
antibody 24 h prior to virus infection resulted in significantly improved survival and weight 
change. A trend toward reduced liver enzyme levels was also observed. MVA-BN-YF, 
therefore, represents a safe alternative to vaccination with live-attenuated YFV.
Keywords: yellow fever, 17D, passive immunization, hamster, modified vaccinia virus ankara, neutralizing 
antibodies
inTrODUcTiOn
Yellow fever (YF), a hemorrhagic disease with jaundice, occurs throughout endemic areas of South 
America and Africa (1, 2). The etiologic agent, YF virus (YFV) is a mosquito-born flavivirus. The 
development of a live-attenuated vaccine in the early twentieth century significantly decreased 
the incidence of YF (3). The live-attenuated 17D vaccine, supplied by seven manufacturers, is 
currently used to protect travelers and also in childhood vaccination programs in many affected 
countries, with millions of doses distributed annually (4). Extensive use of this vaccine to combat 
a recent emergence event in Angola strained the supply of vaccine worldwide and demonstrated 
some limitation of availability and accessibility of the 17D vaccines (5), suggesting a need for an 
alternative vaccine. The virus also continues to emerge in new areas, including a 2017 outbreak in 
Brazil (6) and tens of millions of people could soon be at risk of an urban YF outbreak (7).
Serious adverse events, such as yellow fever vaccine-associated viscerotropic disease (YEL-AVD) 
and neurotropic disease (YEL-AND), have been reported after vaccination with the 17D vaccine. 
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Incidences of YEL-AVD and YEL-AND in the United States are 
reported as 0.4 and 0.8 per 100,000 vaccinations, respectively (8). 
YEL-AVD can be quite severe with a case fatality rate of 65% (9). 
Moreover, incidence rates of adverse events are much higher in 
infants and the elderly (CDC Yellow Book, 2012). Despite the 
infrequency of adverse events, these considerations have sti-
mulated efforts to develop safer YF vaccines.
The modified vaccinia virus Ankara (MVA) is a highly 
attenuated vaccinia virus strain that is non-replicating in humans. 
It has been used extensively as an antigen delivery vector. More-
over, MVA (MVA-BN®/IMVANEX®/IMVAMUNE®) has been 
licensed as safer smallpox vaccine in Europe and Canada. There 
is an extensive safety record of MVA in various vaccine platform 
applications (10–13). We have developed an MVA-vectored YF 
vaccine expressing the poly-protein PreM-E of YFV. In mice, 
the vaccine was shown to induce neutralizing antibodies (nAbs) 
that were increased by a non-mineral oil adjuvant (unpublished 
observation), but efficacy could not be tested in this model.
Challenge of hamsters with the adapted Jimenez strain of 
YFV causes viscerotropic disease after IP inoculation that is 
similar to disease in humans (14, 15). This model has been used 
in the evaluation of both antiviral interventions (16–19) and vac-
cines (20, 21). We have evaluated immunogenicity and efficacy 
of MVA-BN vectored YF and the approved live 17D vaccines in 
this model. Moreover, protective levels of nAb present after vac-
cination with MVA-BN YF were tested in naïve hamsters upon 
passive transfer. The results of these studies provide proof of 




Female golden hamsters (Mesocricetus auratus) with an average 
weight of 100 g were obtained from Charles River Laboratories 
(Wilmington, MA, USA). Following a 48-h quarantine and 5-day 
acclimation period, animals were randomly assigned to groups 
and individually marked with ear tags. All work with animals 
was performed in the Biosafety Level 3 area of the AAALAC-
accredited Laboratory Animal Research Center at Utah State 
University (USU). Hamsters were cared for under an animal 
use protocol approved by the Institutional Animal Care and Use 
Committee Laboratory Animals (IACUC) at USU.
Viruses
YF virus 17D was prepared by passaging in a monolayer culture 
of Vero cells and by harvesting cell culture fluid at the appearance 
of cytopathic effects (CPE). The virus was incubated overnight 
at 4°C followed by quantification by plaque assay in Vero76 cells 
grown in 12-well plates under methylcellulose overlay. After 
5 days of incubation at 37°C and 5% CO2, plates were fixed and 
stained with 0.3% crystal violet-formaldehyde and plaques were 
counted.
The Jimenez strain (South American genotype I, isolated in 
Panama, 1974) was used for hamster challenge studies. The virus 
was adapted by serial passage in hamster liver, as described by 
Tesh and colleagues (15). A seed stock was prepared from livers 
of hamsters, removed 3  days after virus injection and homog-
enized in a 2× volume of sterile phosphate-buffered saline. This 
virus stock had a titer of 106.0 50% cell culture infectious doses 
(CCID50)/mL. Hamsters were challenged IP with 0.2 mL of a 10−4 
dilution of virus stock (20 CCID50/animal).
Vaccine
MVA-BN YF was prepared by inserting the coding region of preM 
and E that are based on the naturally occurring sequence of YFV 
(NCBI Accession No NC_002031) into the MVA-BN® backbone. 
The virus was propagated in primary chicken embryo fibroblast 
cells in serum-free conditions. Montanide (Montanide™ ISA 
720 VG manufactured by SEPPIC S.A., France) was used as a 
non-mineral oil adjuvant mixed with MVA-BN-YF to obtain a 
stable emulsion.
YF-VAX® (Sanofi Pasteur, Swiftwater, PA, USA) 17D YFV 
was obtained as a lyophilized powder and was suspended in the 
manufacturer-supplied buffer. A 1:10 dilution of the vaccine was 
prepared and animals were vaccinated with > 1.0 × 104 plaque 
forming units (pfu) 14 days prior to virus challenge.
neutralization Tests
Antibody levels in serum were quantified using the PRNT50 as 
previously described (21). Briefly, samples of test sera were heat-
inactivated (56°C, 30 min), serial diluted (twofold), and mixed 
with an equal volume of YF 17D virus containing 50–70  pfu, 
incubated for 16–20  h at 2–8°C, and inoculated onto Vero76 
monolayers grown in 12-well plates. Monolayers were covered 
with an overlay medium (0.85% methylcellulose in DMEM with 
10% fetal bovine serum) after adsorption for 1 h at 37°C. Plates 
were fixed and stained with crystal violet-formaldehyde after 
5 days incubation at 37°C. The endpoint was the highest dilution 
of serum inhibiting plaques by 50% or more when compared with 
virus controls.
serum aminotransferase assays
Serum was collected via ocular sinus bleed on 6 dpi. Alanine ami-
notransferase (ALT) (SGPT) reagent (Teco Diagnostics, Anaheim, 
CA, USA) was used, and the protocol was altered for use in 
96-well plates as described previously (14). The aminotransferase 
concentrations were determined per manufacturer’s instructions.
infectious cell culture assay
Test serum samples collected 4  dpi were serially diluted and 
added to Vero 76 cells. Ten days later, CPE was used to identify 
the endpoint of infection. Four replicates were used to calculate 
the CCID50/mL.
Protective efficacy of MVa-Bn YF
Hamsters were randomly assigned to groups of 10–15 animals. 
Animals were immunized s.c. with MVA-BN YF  ±  adjuvant 
on −42 and −14 dpi or s.c. on −14 dpi with YF-VAX. A 10−4 
dilution (102.0 CCID50/mL) of the virus was prepared in minimal 
essential media. Hamsters were challenged on day 0 with Jimenez 
YFV. Serum was collected on −1, 4, and 6 dpi from all surviving 
hamsters for quantification of neutralizing antibody, serum virus, 
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and ALT, respectively. Hamsters were observed at least twice 
daily for mortality, and weights were taken daily from 0 to 8 dpi 
to track weight change. Early euthanasia criteria included lying 
prone, lack of motility or non-responsiveness. Animals that were 
humanely euthanized were recorded as a mortality event on the 
following day, as opposed to animals naturally succumbed to viral 
disease between mortality checks, which were recorded on the 
day they were found.
Passive antibody Transfer
Serum samples collected during the vaccination study were 
used in passive immunization studies. Serum pools were diluted 
1:10–1:100. A volume of 0.5  mL of each serum dilution was 
administered IP to groups of 10 hamsters 24  h prior to virus 
challenge. Serum was collected just prior to virus challenge to 
determine the level of nAb present in the serum at that time. 
Twenty-four hours after antibody treatment, animals were chal-
lenged with virus and followed for mortality, weight change, 
ALT levels, and viremia. A group treated with immune serum 
(IS) from animals vaccinated with MVA-BN YF was sham-
infected and served as a toxicity control. An additional group 
of untreated and uninfected animals was included as normal 
controls. Serum was collected just prior to virus challenge to 
determine the nAb titer of each group 1  day after treatment. 
Serum samples were collected from the retro-orbital sinus 4 and 
6 days after challenge for the assessment of virus titer and serum 
ALT levels, respectively.
statistical Methods
Treatment group comparisons for continuous variables (weight 
change, ALT, and viremia) were performed by one-way ANOVA 
with a Bonferroni multiple comparison post-test analysis com-
paring the antibody-treated groups to the placebo control group.
resUlTs
Vaccination studies
Animals were vaccinated s.c. with 1  ×  108 TCID50 of MVA-
BN-YF, with or without Montanide adjuvant, 42 and 14  days 
prior to challenge with YFV. The approved vaccine YF-VAX 
(Sanofi Pasteur) was used as a positive control and was admin-
istered s.c. 14 days prior to virus challenge. Daily monitoring of 
the animals after immunization revealed no observable adverse 
reaction to vaccination. In accordance with accepted correlates 
of protection, we quantified nAb titers in the serum of animals 
24 h prior to virus challenge. Significantly (p < 0.001) elevated 
levels of nAb were observed in the serum of animals vaccinated 
with MVA-BN YF ± adjuvant or with YF-VAX when compared 
with Tris-buffered saline (TBS) ± adjuvant vaccinated controls 
or with normal controls (Figure 1A). There were also signifi-
cantly (p < 0.05) higher levels of nAb in the serum of animals 
vaccinated with MVA-BN YF with and without adjuvant when 
compared with those from animals vaccinated with YF-VAX 
(Figure  1A). Unexpectedly, an adjuvant effect such as seen 
in mice (data not shown) was not detected (Figure  1A). The 
remainder of serum collected prior to virus challenge was 
pooled by treatment group and used in the subsequent passive 
Ab transfer study described below.
Vaccination with MVA-BN-YF ± adjuvant administered −42 
and −14  days prior to virus challenge resulted in significant 
(p < 0.001) protection through the end of the study (Figure 1B; 
Table  1). In fact, complete survival was observed in all vac-
cinated animals, including those vaccinated with YF-VAX, 
when compared with 40 and 20% survival of vehicle control 
groups that were injected at the same time as vaccine with TBS 
or TBS + adjuvant as vehicle control, respectively (Figure 1B; 
Table 1).
Serum ALT was significantly reduced to baseline levels in all 
animals vaccinated with MVA-BN YF or YF-VAX when com-
pared with respective controls that showed elevated levels of the 
liver enzyme, a typical read-out for YFV infection (Figure 1C; 
Table 1). Animals vaccinated with MVA-BN YF ±  adjuvant or 
with YF-VAX had a similar weight gain to uninfected control 
animals (Figure 1D). Vehicle-vaccinated animals infected with 
YFV experienced weight loss beginning 5 dpi, which continued 
to mortality and is similar to previous results in this model. Some 
weight loss was observed on day 5 in sham-infected animals 
treated with TBS + adjuvant, but this group gained weight after 
that time. Significant improvement in weight gain between 3 
and 6 dpi was observed in hamsters immunized with MVA-BN 
YF ± adjuvant or with YF-VAX (Table 1).
Passive neutralizing antibody Protection 
studies
Naïve hamsters were treated i.p. with 1:10 or 1:100 dilutions of 
pooled IS collected on day 49, either from animals immunized 
with two injections (day 0 and 28) of MVA-BN YF emulsified 
in Montanide adjuvant, or from animals receiving one injec-
tion of YF-VAX (day 28) (Table 2). One day after IS transfer, 
animals were challenged with YFV. A serum sample was taken 
from each animal 4 h prior to virus challenge to determine the 
neutralizing Ab present in the serum at the time of infection.
All of the animals treated with a 1:10 dilution of IS from the 
MVA-BN YF group had detectable (≥1 log10 PRNT50) neutralizing 
Ab titers present in the serum 24 h after treatment (Figure 2A; 
Table 3). The average PRNT50 for animals treated with 1:10 diluted 
MVA-BN YF pooled serum was significantly (p < 0.01) higher 
than that of animals treated with IS from placebo-vaccinated 
animals (Figure 2A; Table 2). Animals treated with a 1:100 dilu-
tion of IS from MVA-BN YF-vaccinated hamsters had PRNT50 
levels at or below the level of detection (Table 2).
All but one animal from the 1:10 dilution of serum from 
animals vaccinated with YF-VAX had titers above the level of 
detection (≥1 log10 PRNT50), but the average was lower than that 
of the MVA-BN YF serum and was not significantly different from 
placebo treatment (Figure 2A; Table 3). All of the animals in the 
group treated with the 1:100 dilution of YF-VAX serum or with 
a 1:10 dilution of serum from placebo-vaccinated animals had 
neutralizing Ab titers at or below the limit of detection (Table 2). 
Neutralizing Ab titers corresponded well with predicted titers 
(Table 2). Higher levels of detectable neutralizing Ab also cor-
responded with increased protection, e.g., in the group treated 
TaBle 1 | Efficacy of vaccination with MVA-BN YF on disease in hamsters challenged with YF virus.
Toxicity controls infected, treated

















MVA-BN YF 1 × 108 TCID50, −42, −14 dpi – – – 10/10 >21.0 ± 0.0 61.9 ± 5.0 4.8 ± 4.2
MVA-BN YF + Adj. 1 × 108 TCID50, −42, −14 dpi 3/3 62.3 ± 9.1 5.0 ± 2.0 10/10 >21.0 ± 0.0 62.8 ± 8.3 4.6 ± 1.9
YF-VAX >5.5 × 104 pfu, −14 dpi 3/3 66.4 ± 18.0 4.3 ± 3.1 10/10 >21.0 ± 0.0 58.4 ± 6.6 4.6 ± 2.5
Tris-buffered saline 
(TBS) + Adj.
−42, −14 dpi 3/3 57.6 ± 5.9 −0.3 ± 6.1 2/10 8.6 ± 1.3 151.6 ± 57.0 −6.2 ± 7.3
TBS −42, −14 dpi 3/3 62.5 ± 5.8 2.3 ± 1.2 6/15 8.4 ± 1.2 156.9 ± 42.3 −8.9 ± 7.1
Norm. controls – 3/3 64.3 ± 2.6 5.0 ± 0.0 – – – –
aSerum ALT levels collected on 6 dpi.
bDifference between weight on 3 and 6 days post-virus challenge representing maximal weight change within this study.
cMean day to death of animals that succumb to disease during the experimental period of 21 days.
FigUre 1 | (a) Log10 plaque reduction neutralization titers to YF virus (YFV) were significantly elevated in hamsters vaccinated with MVA-BN YF ± adjuvant or with 
YF-VAX® compared with animals vaccinated with vehicle [Tris-buffered saline (TBS)] ± adjuvant or untreated normal controls (n = 10/group). (B) Vaccination was 
protective in animals challenged with YFV and (c) serum levels of alanine aminotransferase on day 6 and (D) time-course weight change was improved in hamsters 
immunized with MVA-BN YF or YFVAX® (***p < 0.001, when compared with vehicle).
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with 1:10 dilution of MVA-BN YF serum, further demonstrating 
the protective effect of MVA-BN YF vaccination through neutral-
izing Ab.
Indeed, treatment with the 1:10 dilution of the serum from 
the group vaccinated with MVA-BN YF provided significant 
(p < 0.001) protection to naïve hamsters challenged with YFV as 
compared with placebo (Figure 2B). No significant protection 
was observed after passive administration of a 1:10 dilution 
of serum from animals immunized with YF-VAX, despite a 
higher survival rate when compared with placebo (Figure 2B).
TaBle 2 | The effect of passively transferred immune serum (IS) from animals vaccinated with MVA-BN YF vaccine or with YF-VAX administered 24 h prior to challenge 
with YF virus.
Toxicity controls infected, treated















MVA-BN YF IS 1:10 1.1 ± 0.2 3/3 67 ± 9.0 4.7 ± 2.1 8/10*** 10.0 ± 0.0 88 ± 34 5.3 ± 3.4**
MVA-BN YF IS 1:100 <1.0 ± 0.0 – – – 4/10 8.5 ± 1.0 206 ± 82 −7.5 ± 5.1
YF-VAX IS 1:10 1.0 ± 0.1 3/3 60 ± 6.0 6.0 ± 1.0 3/10 9.0 ± 1.5 162 ± 92 −4.9 ± 5.3
YF-VAX IS 1:100 1.0 ± 0.1 – – – 1/10 8.4 ± 0.9 170 ± 89 −7.5 ± 6.9
Placebo IS 1:10 <1.0 ± 0.0 3/3 73 ± 19 6.0 ± 3.0 1/15 9.3 ± 1.5 169 ± 99 −4.9 ± 8.3
Norm. controls – 3/3 56 ± 6.0 4.7 ± 2.1 – – – –
aAverage log10 neutralizing antibody titer of serum collected 4 h prior to virus challenge and quantified by PRNT50.
bSerum ALT levels collected on 6 dpi.
cDifference between weight on 3 and 6 days post-virus challenge representing maximal weight change within this study.
dMean day to death of animals that succumb to disease during the experimental period of 21 days.
***p < 0.001, **p < 0.01, when compared with placebo treatment.
FigUre 2 | (a) Passive administration of serum from hamsters vaccinated with MVA-BN YF or YF-VAX® resulted in low levels of neutralizing Ab in naïve hamsters 
(n = 10/group) present 24 h after treatment. (B) Survival of hamsters after passive administration of serum from vaccinated hamsters. Passive transfer was only 
significantly protective in hamsters receiving a 1:10 dilution of serum from hamsters vaccinated with MVA-BN YF. (c) Serum alanine aminotransferase on 6 days 
post challenge for individual hamsters passively immunized with various dilutions of immune serum generated after immunization with MVA-BN YF or YF-VAX®.  
(D) Time-course weight change from 0 to 8 dpi.
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Hamsters treated with the 1:10 dilution of MVA-BN YF IS also 
had lower serum ALT titer than all other groups, although this dif-
ference was not significant (p > 0.05) when compared with levels 
in animals treated with serum from placebo-vaccinated animals 
(Figure 2C). Typically, ALT and mortality are generally correla-
tive in this model (14), but in this study, ALT levels in animals 
treated with IS from placebo-vaccinated animals were widely 
distributed and diminished statistical power for this parameter.
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Improved weight change after 4 dpi was observed in hamsters 
in the group receiving the 1:10 dilution of serum from MVA-BN 
YF immunized animals (Figure  2D). This weight gain was 
similar to that of sham-infected groups. Indeed, the difference 
in weight between 3 and 6  dpi was significantly (p  <  0.01) 
improved in animals treated with 1:10 MVA-BN YF serum 
group when compared with infected hamsters treated with IS 
from placebo-vaccinated groups (Table 2). All other groups had 
weight loss similar to that of animals treated with serum from 
vehicle-vaccinated animals.
DiscUssiOn
The investigational YFV vaccine MVA-BN YF provided protec-
tion in a hamster model of disease, as indicated by significant 
improvement in survival, weight change, and liver enzyme levels 
in the blood when compared with placebo vaccination. Protection 
corresponded with induced neutralizing Ab titers, which was 
demonstrated by passive transfer studies. Although millions of 
doses of the currently approved 17D-based vaccine have been used 
to protect from YFV infection and disease, a recent outbreak in 
Angola demonstrated the limitation of the global stockpile of this 
vaccine and underscores the potential need for the development 
of a safe and effective vaccine. Use of MVA-BN YF would improve 
some aspects of the current YFV vaccine, including reducing or 
eliminating rare adverse events associated with current vaccines 
(22). Although MVA-BN YF utilizes a live-attenuated virus, this 
replication deficient virus demonstrated a high level of safety and 
immunogenicity in around 7,000 vaccinated individuals (23), 
even in fully immune compromised mice and primates (24–26). 
The results reported herein suggest further testing toward clinical 
development is warranted.
The accepted immune correlate of protection against YF 
is neutralizing antibodies (27). A lethal primate challenge 
model of YF was used to assess the minimal protective level 
of neutra lizing Ab elicited by the 17D YF vaccine, which was 
determined to be ≥0.7 log10 neutralization index of ≥0.7 
(28). Natural infec tion or effective vaccination will elicit the 
production of neutralizing antibody, which will persist in the 
serum, protecting from subsequent challenge with the same 
virus or serotype. We have also demonstrated protection after 
immunization with an investigational vaccine in a hamster 
model of YFV infection and demonstrated neutralizing anti-
body as a correlate of protection (20, 21). Significantly elevated 
levels of neutralizing antibody were observed in hamsters vac-
cinated with MVA-BN YF, which were protective in passive 
administration studies. Typically, MVA-BN-based vaccines 
provide transient and localized expression of the gene of inter-
est in animal models. We anticipate that preM and E expression 
will be inactive 2  weeks after vaccination with MVA-BN YF. 
Protection observed in these studies would be due to elicited 
immune responses as a result of vaccination.
Vaccination with YF-VAX was included as a control, 
although the different nature of YF-VAX and MVA-BN YF 
precluded a direct comparison. The currently approved 
YF-VAX is a live-attenuated vaccine that confers protection after 
a single dose, while MVA-BN YF is replication incompetent and 
has a relatively short period of antigen expression and would 
likely require a booster vaccination in a clinical setting. The 
potential disadvantage of a required booster vaccination is, in 
our view, compensated by a very good safety profile of the non-
replicative MVA-BN YF and precludes the adverse events that 
are associated with YF-VAX. Previous studies demonstrated 
a greater degree of stimulation of neutralizing Ab production 
after immunization with YF-VAX, but a greater vaccine dose 
(>4.7 log10 pfu) was used in these studies (20, 21). The predicted 
protective value of a PRNT50 value of 40 (1.6 log10 PRNT50) was 
also higher than what was observed in this study, but this is 
likely well above functional protective levels and other stud-
ies indicate that Ab levels >1.0 log10 PRNT50 are protective in 
vaccinee (29). The addition of the non-mineral oil Montanide 
to MVA-BN YF did not increase antibody titers compared to 
the non-adjuvanted vaccine. This was in contrast to previous 
unpublished findings in BALB/c mice. However, differences 
in the mouse were greater after a single vaccination and the 
hamster studies reported here used a prime-boost vaccination 
schedule only.
Taken together, vaccination of hamsters with an MVA-based 
YF vaccine provided full protection that was comparable to the 
licensed 17D YF vaccine, and this protection could be transferred to 
naïve hamsters through serum, confirming that induced neutra-
lizing antibodies are a correlate of protection. MVA-BN YF may 
represent a safe alternative to 17D YF vaccines.
eThics sTaTeMenT
This study, including veterinary care and experimental proce-
dures, was conducted in accordance with the approval of the 
Institutional Animal Care and Use Committee of Utah State 
University (USU) under the approved protocols #1231 and 2248. 
TaBle 3 | Neutralizing antibody titers present in serum 24 h after treatment with 
a 1:10 dilution of immune serum.
log10 PrnT50a (survival-y/nb)
Treatment 1:10 MVa-Bn YF 1:10 YF-VaX 1:10 Placebo
Animal 
number
1 1.3 (y) 1.0 (y) <1.0 (n)
2 1.0 (y) 1.3 (n) 1.0 (n)
3 1.0 (n) 1.0 (n) <1.0 (n)
4 1.3 (y) 1.0 (n) <1.0 (n)
5 1.0 (n) 1.0 (n) <1.0 (n)
6 1.3 (y) 1.0 (n) <1.0 (n)
7 1.0 (y) 1.0 (n) <1.0 (y)
8 1.0 (y) <1.0 (y) <1.0 (n)
9 1.0 (y) 1.0 (y) <1.0 (n)






The eventual survival (y) or mortality (n) through 21 dpi is indicated in parentheses.
aThe log10 50% of control.
bDid the animal survive (yes or no)?
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